When is good regulatory writing "good enough"?

Here's another blog post worth repeating (originally published in 2010):

We do not talk much on this blog regarding the use of language or the application of terms in science writing. Principal reason is that much of what we see in regulatory submission documents is genuinely “good enough.” However, others do not necessarily see it that way. I want to share with you how discussions in review roundtables can end up getting focused at really absurd levels of detail with a misapplied sense of establishing quality communication. 

In our consulting work, we try to be disciplined during our document reviews and only comment on language when it truly obscures or alters meaning. Being grammatically perfect in regulatory submission documents is a nice notion, but in practice consumes way too much time and organizational energy and will yield little in terms of outcomes.

We share this point with people all the time...but at times the advice goes unheeded and even worse…at times people just do not know when to move on and address real big concerns in their documents.

A case in point is a situation I observed regarding a long winded discussion in a review meeting over the use of the term “very critical”. The term “critical” in a medical sense means: of a patient's condition having unstable and abnormal vital signs and other unfavorable indicators. In theory, the meaning of critical is a black-or-white proposition without qualifications regarding gradation. Something is either critical or it is not. Therefore there should be no adverbs, like “very” in front of the term “critical” to connote a measureable degree of criticality. In this roundtable review the team got caught up in a 30 minute discussion that involved only two people arguing whether to use the term “very critical” or change it to “critical.”

Being pragmatic, I’d have to say: “Guys what are you thinking? You hold a team hostage for 30 minutes to argue over grammatical accuracy? To argue over something that will not matter when and if read by a regulatory reviewer. There were 10 professionals sitting in the room and 8 did nothing for 30 minutes. Cost of salaries alone is enough argument to say “Forget about it, let’s move on…we cannot afford to argue over such insignificant detail.” When we add in the opportunity cost (what these 10 people collectively could have been doing with their time), then for sure you have to make the argument.

This above episode gets played out time and time again in review sessions all over the pharma and medical device industries and is the reason why I am steadfast in my position that the vast majority of people involved in authorship and review do not know the answer to the question “How do you know when is good, good enough?” The end result is inordinate amounts of time can be applied at the wrong level of detail in reports and submission documents.